Blog / tirzepatide
Tirzepatide for Sleep Apnea: What SURMOUNT-OSA Shows and What to Track
What the SURMOUNT-OSA trial found about tirzepatide and sleep apnea, what it does not show, and what to record in a GLP-1 tracker.
By Peppy Team6 min read
Sleep apnea and weight have a long and well known link. In late 2024 that link got a new chapter. A large trial called SURMOUNT-OSA tested tirzepatide in adults with obesity and moderate to severe obstructive sleep apnea, and the results led to a new FDA approval.
This post explains what the trial measured, what the researchers reported, and what that means in plain terms. It also covers the kind of records that make a conversation with your provider easier if you use a GLP-1 tracker while being treated for sleep apnea. Nothing here is advice about whether a medicine is right for you. That decision belongs to you and a licensed healthcare provider.
What obstructive sleep apnea is
The National Heart, Lung, and Blood Institute describes sleep apnea as a condition where breathing stops and restarts many times during sleep. Obstructive sleep apnea, often shortened to OSA, is the most common type. It happens when the upper airway becomes blocked again and again through the night.
NHLBI lists obesity as one of the factors that can narrow the airway and raise the risk of OSA. It also notes that untreated sleep apnea raises the risk of stroke, heart attack and other serious problems.
Diagnosis usually involves a sleep study. Common treatments include breathing devices such as CPAP machines and lifestyle changes. Until recently, there was no medicine approved to treat OSA itself.
What the SURMOUNT-OSA trial tested
SURMOUNT-OSA was actually two phase 3 trials run side by side. The results were published in the New England Journal of Medicine in 2024 by Malhotra and colleagues.
Here is how it was set up:
- Who took part: adults with moderate to severe obstructive sleep apnea and obesity.
- Two groups of people: trial 1 enrolled people who were not using positive airway pressure (PAP) therapy. Trial 2 enrolled people who were already using PAP.
- Comparison: participants were randomly assigned to tirzepatide or placebo, in a double blind design.
- Length: 52 weeks.
- Dose in the study: each person received the highest dose they could tolerate within the trial protocol. This was a research design choice, not a guide for anyone outside the study.
The main measure: AHI
The primary end point was the change in the apnea hypopnea index, or AHI. AHI counts how many times per hour breathing stops (apnea) or becomes shallow (hypopnea) during sleep. A higher number means more interruptions.
At the start, the average AHI was about 51 events per hour in trial 1 and about 50 events per hour in trial 2. Both are in the severe range used in sleep medicine.
What the researchers reported
According to the published abstract, after 52 weeks:
- In trial 1 (no PAP), AHI fell by an average of about 25 events per hour with tirzepatide, compared with about 5 with placebo.
- In trial 2 (using PAP), AHI fell by an average of about 29 events per hour with tirzepatide, compared with about 5.5 with placebo.
The researchers also reported improvements in several secondary measures compared with placebo. These included body weight, hypoxic burden (a measure of how much oxygen levels drop during breathing events), a blood marker of inflammation called hsCRP, systolic blood pressure, and how people rated their own sleep.
The most commonly reported side effects with tirzepatide were gastrointestinal, and most were described as mild to moderate.
Why weight matters here
The trial does not suggest that tirzepatide opens the airway directly. The FDA announcement from December 20, 2024 says the improvement in AHI is likely related to body weight reduction. That fits the long known link between excess weight and OSA risk.
What the FDA approved
Based on these studies, the FDA approved Zepbound (tirzepatide) for moderate to severe OSA in adults with obesity. The agency called it the first drug treatment option for certain patients with obstructive sleep apnea. The approval is for use together with a reduced calorie diet and increased physical activity.
The FDA also pointed out that the trials enrolled 469 adults without type 2 diabetes. That detail matters, because results in one group of people do not automatically carry over to everyone.
What the trial does not tell you
It is easy to read a headline and assume more than the study showed. A few limits are worth keeping in mind:
- It lasted one year. Longer term results are a separate question.
- It studied a specific group. Adults with obesity and moderate to severe OSA, without type 2 diabetes.
- It was compared with placebo, not with surgery or other treatments.
- It did not replace PAP. One trial included people who kept using PAP. Whether anyone changes their PAP use is a decision for their sleep specialist.
- Individual results varied. Averages hide a wide range of responses.
Your provider is the right person to weigh what this research means for your own situation.
What to track if you are treated for sleep apnea with a GLP-1
If your provider has started you on tirzepatide or another GLP-1 for sleep apnea, good records help both of you see what is changing. You do not need to interpret anything yourself. You just need a clean, honest log.
Doses and timing
Log each dose on the day you take it, along with the dose your provider gave you. Note missed or late doses too. Gaps in a dose history make it harder to tell whether a change in sleep or weight lines up with treatment.
Weight over time
The FDA linked the AHI improvement to weight reduction, so a steady weight record is useful. Weigh in under similar conditions each time, such as the same time of day. Look at the trend across weeks rather than any single number.
Sleep notes
Keep short, factual notes rather than judgments. For example:
- Whether you used your PAP device that night, if you have one
- How rested you felt on waking, on a simple scale
- Anything a partner mentioned, like snoring or pauses in breathing
These notes are for your provider to review. They are not a way to diagnose or rate your own sleep apnea.
Side effects
The trial reported mostly gastrointestinal side effects. Note what you notice, when it started, how strong it felt, and how long it lasted. Bring that list to your appointments.
Sleep study results
If you have a follow up sleep study, write down the date and the AHI your provider shares with you. Keeping those values next to your dose and weight history gives a clear picture over months.
Keeping a record in Peppy
Peppy is a GLP-1 tracker for iPhone that keeps this kind of record in one place. You can log each dose against the schedule your provider set, get dose reminders, and review a full dose history with missed and on-time doses on a calendar.
It also charts weight against your goal and lets you log side effect check-ins from mild to severe, which you can see next to your doses. The help page on weight, side effects and history shows how those pieces fit together. If you take tirzepatide, the tirzepatide tracker page covers that setup.
If your treatment comes in a vial and you want to check how the numbers fit together, the free peptide calculator works through vial strength, water added and the dose your provider gave you. It is a math helper for the numbers you already have, not a source of dose advice.
Your data stays on your iPhone and your own iCloud backup. There is no account to create.
The takeaway
SURMOUNT-OSA showed that, in adults with obesity and moderate to severe obstructive sleep apnea, tirzepatide reduced breathing interruptions during sleep compared with placebo over one year. The FDA approved it for that use in December 2024 and linked the benefit to weight reduction.
Whether that applies to you is a question for your provider. What you can control is the quality of your records. Consistent dose logs, weight trends, simple sleep notes and side effect check-ins give your provider a much clearer view than memory alone.
More from the blog

semaglutide6 min read
Semaglutide Benefits: What the Evidence Says and How to Track Your Progress
A plain guide to semaglutide benefits backed by FDA approvals and research, what they do not promise, and how to track your own progress with your provider.
- semaglutide
- glp 1
- weight

glp 16 min read
What Orforglipron Research Shows About Oral GLP-1 Pills and What to Track
A plain guide to the ATTAIN-1 and ACHIEVE-1 orforglipron trials, how a daily GLP-1 pill differs from injectables, and what to record.
- glp 1
- dose log
- side effects

semaglutide6 min read
CagriSema Research Explained: What the REDEFINE Trials Show and What to Track
A plain guide to CagriSema research: what the REDEFINE trials reported, what is still unknown, and what to track in a peptide tracker.
- semaglutide
- glp 1
- tracking
